JP7851034B2 - 選択されたプリンホスホルアミデートの立体選択的製造 - Google Patents

選択されたプリンホスホルアミデートの立体選択的製造

Info

Publication number
JP7851034B2
JP7851034B2 JP2023512073A JP2023512073A JP7851034B2 JP 7851034 B2 JP7851034 B2 JP 7851034B2 JP 2023512073 A JP2023512073 A JP 2023512073A JP 2023512073 A JP2023512073 A JP 2023512073A JP 7851034 B2 JP7851034 B2 JP 7851034B2
Authority
JP
Japan
Prior art keywords
compound
formula
mixture
diastereomer
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023512073A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023538594A (ja
JP2023538594A5 (https=
Inventor
アデル ムーサ
ナラヤン チョウドリー
Original Assignee
アテア ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アテア ファーマシューティカルズ， インコーポレイテッド filed Critical アテア ファーマシューティカルズ， インコーポレイテッド
Publication of JP2023538594A publication Critical patent/JP2023538594A/ja
Publication of JP2023538594A5 publication Critical patent/JP2023538594A5/ja
Application granted granted Critical
Publication of JP7851034B2 publication Critical patent/JP7851034B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/02—Phosphorylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Luminescent Compositions (AREA)
JP2023512073A 2020-08-19 2021-08-19 選択されたプリンホスホルアミデートの立体選択的製造 Active JP7851034B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063067726P 2020-08-19 2020-08-19
US63/067,726 2020-08-19
US202063074302P 2020-09-03 2020-09-03
US63/074,302 2020-09-03
US202063094759P 2020-10-21 2020-10-21
US63/094,759 2020-10-21
US202063129306P 2020-12-22 2020-12-22
US63/129,306 2020-12-22
PCT/US2021/046778 WO2022040473A1 (en) 2020-08-19 2021-08-19 Stereoselective manufacture of selected purine phosphoramidates

Publications (3)

Publication Number Publication Date
JP2023538594A JP2023538594A (ja) 2023-09-08
JP2023538594A5 JP2023538594A5 (https=) 2024-08-27
JP7851034B2 true JP7851034B2 (ja) 2026-04-24

Family

ID=80323295

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023512073A Active JP7851034B2 (ja) 2020-08-19 2021-08-19 選択されたプリンホスホルアミデートの立体選択的製造

Country Status (10)

Country Link
US (1) US20230331751A1 (https=)
EP (1) EP4200309A4 (https=)
JP (1) JP7851034B2 (https=)
KR (1) KR20230053640A (https=)
CN (1) CN115884977A (https=)
AU (1) AU2021327241A1 (https=)
CA (1) CA3173661A1 (https=)
MX (1) MX2023002064A (https=)
TW (1) TW202214260A (https=)
WO (1) WO2022040473A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL288737B (en) 2017-02-01 2022-09-01 Atea Pharmaceuticals Inc Hemisulfate nucleotide salt for treatment of hepatitis c virus
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
IL308921A (en) 2021-06-17 2024-01-01 Atea Pharmaceuticals Inc Combination anti-HCV therapy is beneficial
WO2023173196A1 (en) 2022-03-18 2023-09-21 Enveric Biosciences Canada Inc. C4-carboxylic acid-substituted tryptamine derivatives and methods of using
CN121628124B (zh) * 2026-02-05 2026-04-10 山东鲁源化工科技有限公司 一种高热稳定性聚磷酸酯阻燃剂及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014008236A1 (en) 2012-07-03 2014-01-09 Bristol-Myers Squibb Company Process for preparing diastereomerically enriched phosphoramidate derivatives of nucleoside compounds for treatment of viral infections
JP2018507261A (ja) 2015-03-06 2018-03-15 アテア ファーマシューティカルズ， インコーポレイテッド ＨＣＶ治療に対するβ−Ｄ−２’−デオキシ−２’−α−フルオロ−２’−β−Ｃ−置換−２−修飾−Ｎ６−置換プリンヌクレオチド
JP2019526596A (ja) 2016-09-07 2019-09-19 アテア ファーマシューティカルズ， インコーポレイテッド Ｒｎａウイルス治療に対する２’−置換−ｎ６−置換プリンヌクレオチド
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2021173713A1 (en) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014008236A1 (en) 2012-07-03 2014-01-09 Bristol-Myers Squibb Company Process for preparing diastereomerically enriched phosphoramidate derivatives of nucleoside compounds for treatment of viral infections
JP2018507261A (ja) 2015-03-06 2018-03-15 アテア ファーマシューティカルズ， インコーポレイテッド ＨＣＶ治療に対するβ−Ｄ−２’−デオキシ−２’−α−フルオロ−２’−β−Ｃ−置換−２−修飾−Ｎ６−置換プリンヌクレオチド
JP2019526596A (ja) 2016-09-07 2019-09-19 アテア ファーマシューティカルズ， インコーポレイテッド Ｒｎａウイルス治療に対する２’−置換−ｎ６−置換プリンヌクレオチド
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2021173713A1 (en) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. Org. Chem. ，2015年，80，4994-5003

Also Published As

Publication number Publication date
WO2022040473A1 (en) 2022-02-24
JP2023538594A (ja) 2023-09-08
KR20230053640A (ko) 2023-04-21
EP4200309A1 (en) 2023-06-28
US20230331751A1 (en) 2023-10-19
MX2023002064A (es) 2023-03-16
TW202214260A (zh) 2022-04-16
EP4200309A4 (en) 2025-03-19
CN115884977A (zh) 2023-03-31
AU2021327241A1 (en) 2023-04-20
CA3173661A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
JP7851034B2 (ja) 選択されたプリンホスホルアミデートの立体選択的製造
JP7441947B2 (ja) Ｍｃｌ１阻害剤を調製するためのプロセス及び中間体
EP3096763B1 (en) Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
CN103517911B (zh) 雷帕霉素在c-42位上的区域选择性酰化
EP3083630B1 (en) Process methods for phosphatidylinositol 3-kinase inhibitors
JP2025090640A (ja) 均質オリゴマーを調製するためのキラル試薬
CA2801101A1 (en) Process for preparing a biphenyl-2-ylcarbamic acid
JP2022513151A (ja) 重水素化大環状化合物の調製方法
CN102924454B (zh) 恩替卡韦的合成方法
US20210147466A1 (en) Improved processes for the preparation of guadecitabine and intermediates thereof
HK40121275A (en) Processes and intermediates for preparing mcl1 inhibitors
TW202537962A (zh) 抑制α-V β-1整合素
HK40081488A (en) Processes and intermediates for preparing mcl1 inhibitors
HK40081488B (en) Processes and intermediates for preparing mcl1 inhibitors
CN102464691A (zh) 制备抗病毒组合物的方法及其中间体的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240819

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240819

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260310

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260407

R150 Certificate of patent or registration of utility model

Ref document number: 7851034

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150